Expression of periostin in small cell lung cancer and its effect on chemoresistance_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WANG Xiaojin ¹ , LI Xiaojian ¹ , CHENG Hua ¹ , LI Wei ² , ZHONG Hongcheng ¹ , ZHONG Beilong ¹ ,  CAO Qingdong ¹

1. Department of Cardiothoracic Surgery, The Fifth Hospital Affiliated to Sun Yat-sen University, Zhuhai, 519000, Guangdong, P.R.China;
2. Department of Pathology, The Fifth Hospital Affiliated to Sun Yat-sen University, Zhuhai, 519000, Guangdong, P.R.China;

Corresponding author：

CAO Qingdong, Email: 15013813866@163.com

Keywords：

Periostin; small cell lung cancer; chemoresistance; recombinant plasmid

DOI：

10.7507/1007-4848.201706035

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To detect the difference of periostin expression in small cell lung cancer (SCLC) cell, and explore its effect on chemoresistance of SCLC patients. Methods The expression of periostin in mRNA and protein was detected by RT-PCR and Western blot analysis in SCLC H69 and multidrug resistant strain H69AR. The expression of periostin was up-regulated by recombinant plasmid-periostin in H69 cell. The survival rate in the transfected group was different from that of the negative control group and uninterrupted group. Results The expression of periostin mRNA and protein in the sensitive strain H69 was lower than that of the multidrug resistant strain H69AR (P<0.05). The recombinant periostin-plasmid was transfected into H69 cells and at the same concentration of chemotherapeutic drugs (cisplatin, etoposide) the survival rate increased significantly (P<0.05). The positive expression rate of periostin in SCLC tissues was 67.44%, and the sensitivity of the chemotherapy group was lower than that of the drug resistant group (P<0.05). Conclusion The expression of periostin in SCLC cell H69 is significantly lower than that of the multidrug resistant strain H69AR and overexpression of periostin increases resistance of the sensitive strain H69 and hence periostin may be involved in SCLC chemoresistance.

Citation： WANG Xiaojin, LI Xiaojian, CHENG Hua, LI Wei, ZHONG Hongcheng, ZHONG Beilong, CAO Qingdong. Expression of periostin in small cell lung cancer and its effect on chemoresistance. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2018, 25(6): 516-521. doi: 10.7507/1007-4848.201706035 Copy

1.	Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer, 2012, 13(2): 115-122.
2.	Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res, 2015, 21(10): 2244-2255.
3.	Altan M, Chiang AC. Management of small cell lung cancer: progress and updates. Cancer J, 2015, 21(5): 425-433.
4.	Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase Ⅱ study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol, 2016, 77(4): 713-722.
5.	Schabath MB, Nguyen A, Wilson P, et al. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer, 2014, 86(1): 14-21.
6.	Takeshita S, Kikuno R, Tezuka K, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J, 1993, 294 (Pt 1): 271-278.
7.	Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplastic processes. Folia Histochem Cytobiol, 2015, 53(2): 120-132.
8.	Moniuszko T, Wincewicz A, Koda M, et al. Role of periostin in esophageal, gastric and colon cancer. Oncol Lett, 2016, 12(2): 783-787.
9.	Zhang Y, Yuan D, Yao Y, et al. Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy. Tumour Biol, 2017, 39(5): 1010428317698367.
10.	Ma D, Lu H, Xu L, et al. Mechanical loading promotes Lewis lung cancer cell growth through periostin. In Vitro Cell Dev Biol Anim, 2009, 45(8): 467-472.
11.	Liu Y, Li F, Gao F, et al. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Tumour Biol, 2016, 37(11): 15283-15291.
12.	Santarpia M, Daffinà MG, Karachaliou N, et al. Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res, 2016, 5(1): 51-70.
13.	Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer, 2015, 121(5): 664-672.
14.	Almquist D, Mosalpuria K, Ganti AK. Multimodality therapy for limited-stage small-cell lung cancer. J Oncol Pract, 2016, 12(2): 111-117.
15.	Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology, 2007, 132(4): 1447-1464.
16.	Hong LZ, Wei XW, Chen JF, et al. Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncol Lett, 2013, 6(6): 1595-1603.
17.	Ouyang G, Liu M, Ruan K, et al. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett, 2009, 281(2): 213-219.
18.	Xiao ZM, Wang XY, Wang AM. Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem, 2015, 62(3): 401-406.

1. Gaspar LE, McNamara EJ, Gay EG, et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. Clin Lung Cancer, 2012, 13(2): 115-122.
2. Pietanza MC, Byers LA, Minna JD, et al. Small cell lung cancer: will recent progress lead to improved outcomes? Clin Cancer Res, 2015, 21(10): 2244-2255.
3. Altan M, Chiang AC. Management of small cell lung cancer: progress and updates. Cancer J, 2015, 21(5): 425-433.
4. Trafalis DT, Alifieris C, Stathopoulos GP, et al. Phase Ⅱ study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemother Pharmacol, 2016, 77(4): 713-722.
5. Schabath MB, Nguyen A, Wilson P, et al. Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients. Lung Cancer, 2014, 86(1): 14-21.
6. Takeshita S, Kikuno R, Tezuka K, et al. Osteoblast-specific factor 2: cloning of a putative bone adhesion protein with homology with the insect protein fasciclin I. Biochem J, 1993, 294 (Pt 1): 271-278.
7. Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplastic processes. Folia Histochem Cytobiol, 2015, 53(2): 120-132.
8. Moniuszko T, Wincewicz A, Koda M, et al. Role of periostin in esophageal, gastric and colon cancer. Oncol Lett, 2016, 12(2): 783-787.
9. Zhang Y, Yuan D, Yao Y, et al. Predictive and prognostic value of serum periostin in advanced non-small cell lung cancer patients receiving chemotherapy. Tumour Biol, 2017, 39(5): 1010428317698367.
10. Ma D, Lu H, Xu L, et al. Mechanical loading promotes Lewis lung cancer cell growth through periostin. In Vitro Cell Dev Biol Anim, 2009, 45(8): 467-472.
11. Liu Y, Li F, Gao F, et al. Periostin promotes the chemotherapy resistance to gemcitabine in pancreatic cancer. Tumour Biol, 2016, 37(11): 15283-15291.
12. Santarpia M, Daffinà MG, Karachaliou N, et al. Targeted drugs in small-cell lung cancer. Transl Lung Cancer Res, 2016, 5(1): 51-70.
13. Byers LA, Rudin CM. Small cell lung cancer: where do we go from here? Cancer, 2015, 121(5): 664-672.
14. Almquist D, Mosalpuria K, Ganti AK. Multimodality therapy for limited-stage small-cell lung cancer. J Oncol Pract, 2016, 12(2): 111-117.
15. Erkan M, Kleeff J, Gorbachevski A, et al. Periostin creates a tumor-supportive microenvironment in the pancreas by sustaining fibrogenic stellate cell activity. Gastroenterology, 2007, 132(4): 1447-1464.
16. Hong LZ, Wei XW, Chen JF, et al. Overexpression of periostin predicts poor prognosis in non-small cell lung cancer. Oncol Lett, 2013, 6(6): 1595-1603.
17. Ouyang G, Liu M, Ruan K, et al. Upregulated expression of periostin by hypoxia in non-small-cell lung cancer cells promotes cell survival via the Akt/PKB pathway. Cancer Lett, 2009, 281(2): 213-219.
18. Xiao ZM, Wang XY, Wang AM. Periostin induces chemoresistance in colon cancer cells through activation of the PI3K/Akt/survivin pathway. Biotechnol Appl Biochem, 2015, 62(3): 401-406.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Expression of periostin in small cell lung cancer and its effect on chemoresistance

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content